Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperuricemia has been associated with adverse cardiovascular outcomes in patients with chronic kidney disease (CKD). Although uric acid lowering therapy has shown short-term cardiovascular benefits, long-term effects remain uncertain. Previous studies have shown ineffectiveness of allopurinol in slowing CKD progression, though they were not primarily designed to assess cardiovascular endpoints. This study aimed to evaluate whether allopurinol, compared with placebo, reduces the risk of major adverse cardiovascular events (MACE) in CKD patients. Secondary objectives included assess its impact on all-cause mortality, need for renal replacement therapy (RRT), and ≥50% decline in estimated glomerular filtration rate (eGFR). Here, we present the descriptive of baseline characteristics of this study population
This study was a multi-centre, double-blind, placebo-controlled randomized trial conducted across 13 centres in India. Clinically stable adults with CKD (eGFR 10–45 ml/min/1.73m²) and serum uric acid ≥6 mg/dl were enrolled. Patients with acute gout, allopurinol hypersensitivity, chronic liver disease, or participation in another interventional study were excluded. Participants were randomized to receive either allopurinol 100 mg/day or a matching placebo, with a planned follow-up of 36 months. The trial was registered in the Clinical Trials Registry of India (CTRI/2020/05/025044).
A total of 890 participants were enrolled, with a mean age of 51 ± 12 years; 66% were male. CKD etiology was unknown in 43% of participants, while diabetic kidney disease and chronic interstitial nephritis accounted for 18% and 16%, respectively. The median CKD duration was 33 (6, 47) months. Histories of hypertension, diabetes, renal stone disease, coronary artery disease and smoking were present in 82%, 27%, 18%, 7% and 18% of patients, respectively (Table 1). Baseline mean serum creatinine, eGFR and uric acid were 3 ± 1 mg/dl, 26 ± 9 and 8 ± 1 mg/dl (Table 2).
This multi-centre trial represents the largest study evaluating allopurinol’s effect on cardiovascular outcomes in CKD patients with hyperuricemia.
